High Risk, HR+, HER2- Early Breast Cancer: CDK4/6 Inhibitor Trials

0 SAR
Checkout

Overview

Welcome to this educational video on the efficacy and safety of CDK4/6 inhibitors in oncology. In this presentation, Dr. Johnston reviews key clinical evidence, highlighting treatment outcomes, patient benefits, and important safety considerations associated with CDK4/6 inhibitor therapy. The discussion aims to provide healthcare professionals with a concise overview of current data to support informed treatment decisions and optimize patient care.


This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Highlight how Abemaciclib benefits node-positive, high-risk EBC patients by improving survival and providing long-lasting protection from recurrence with just 2 years of treatment.

     

     

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    CMAT-39070


Related Classes